Septerna Inc. Common Stock (SEPN)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Septerna as a Graham-style analyst, not a drug-development cheerleader. The company is a clinical-stage biotech working on oral small molecules for GPCR targets in endocrine, immunology, inflammation, and metabolic disease. The revenue profile has changed sharply: in fiscal 2023, the year ended 2023-12-31, revenue was $151,000 and net income was $4.2M; in fiscal 2024, the year ended 2024-12-31, revenue was $1.1M and net loss was $71.8M; in fiscal 2025, the year ended 2025-12-31, revenue was $46.0M and net loss was $48.9M. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $26.5M and net loss $8.6M; in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $26.7M and net loss $13.0M. That is real top-line momentum, but not consistent profitability. The lone profitable filed quarter shown is fiscal Q3 2025, the quarter ended 2025-09-30, with $21.5M revenue and $8.2M net income. Debt is modest: D/E 0.06. FairStock's TTM free cash flow is $105.1M and FCF yield 6.2%, while Altman Z-Score is 5.82, but Piotroski F-Score is 3/9 and ROE/ROCE are negative. At the 2026-10-13 close of $36.42, market cap $1.7B, P/B 4.30, and negative P/E -68.71. The Lynch category is TURNAROUND, based on a loss in the latest year after earlier profits. Without durable earnings or a proven moat, the price already anticipates clinical success. I see speculative promise, not a margin-of-safety bargain.

In plain English: Septerna is a small biotech that is developing oral medicines for hormone and immune diseases. It is not yet steadily profitable and depends on drug trials and partnership revenue. At $36.42 a share, the price looks expensive compared with its current profits and accounting value, even though it has some cash flow and little debt.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer